Ken Griffin’s LogicBio Therapeutics, Inc. Common Stock LOGC Stock Holding History

Ken Griffin’s Portfolio LOGC Stock Details LOGC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-21,500	Closed	-$8K	–	14121
2022 Q2	$8K	Buy	21,500 +2,700	+14%	+$1.37K	﹤0.01%	12642
2022 Q1	$13K	Buy	+18,800	New	+$20.6K	﹤0.01%	13352

Ken Griffin's LOGC Position: Q4 2022 in Review

Ken Griffin sold out of LogicBio Therapeutics, Inc. Common Stock (LOGC) in Q4 2022, closing a stake of 115,925 shares — an estimated $32K sold.

Ken Griffin first reported a position in LOGC in Q4 2020 and held it in 4 quarters. The position peaked at $248K in Q4 2020. 0 funds tracked by Wall St. Rank hold LOGC as of Q4 2022.

Ken Griffin reported no remaining LogicBio Therapeutics, Inc. Common Stock position as of Q4 2022 after selling out during the quarter.
Ken Griffin sold 115,925 LogicBio Therapeutics, Inc. Common Stock shares in Q4 2022, an estimated $32K.
Ken Griffin first reported a position in LogicBio Therapeutics, Inc. Common Stock in Q4 2020 and held it in 4 quarters.
Ken Griffin's LogicBio Therapeutics, Inc. Common Stock position peaked at $248K in Q4 2020.
0 funds tracked by Wall St. Rank held LogicBio Therapeutics, Inc. Common Stock as of Q4 2022.

Based on Citadel Advisors's 13F filing for Q4 2022, filed 14 Feb 2023.